Case Report: FIA plus venetoclax in a patient on hemodialysis

Frontiers in Oncology 2026 Open access

Read full text
Authors: Jacob E. Herstein, Kayleigh R. Marx, J. Michael Savoy, Wei Ying Jen, Musa E. Yilmaz, Nicholas J. Short, Ghayas C. Issa, Farhad Ravandi, Tapan M. Kadia, Naval G. Daver, Courtney D. DiNardo
DOI: 10.3389/fonc.2025.1740357
Cited by: 1
References: 21

Abstract

The safe and effective delivery of curative cytotoxic chemotherapy for acute myeloid leukemia (AML) in patients receiving intermittent hemodialysis (IHD) for end-stage renal disease (ESRD) remains a clinical challenge; pharmacological and logistical barriers necessitate close interdisciplinary coordination. In this case, we report a 65-year-old female patient with chronic ESRD on IHD and newly diagnosed AML who achieved complete remission (CR) after treatment with fludarabine, idarubicin, and cytarabine plus venetoclax (i.e., FIA + venetoclax).

Fields of Study & Subjects

Acute Myeloid Leukemia Research Chemotherapy-induced organ toxicity mitigation Chronic Myeloid Leukemia Treatments

Publication details

Journal / source
Frontiers in Oncology
Publisher
Frontiers Media SA
Volume
15
Pages
1740357–1740357
Publication date
15 January 2026
Language
EN